Worth reading
90Important
Scored from 2 of 5 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Details of issuance or disposal
Change in the Use of Proceeds for Series 20 Stock Acquisition Rights through a Third-Party Allotment (with an Exercise Price Adjustment Provision) and Series 16 Stock Acquisition Rights
発行・処分する株式数
Exercise was completed for all 190,501 Series 20 stock acquisition rights (19,050,100 shares). Exercise was completed for all 164,000 Series 16 stock acquisition rights (16,400,000 shares).
Amount of funds to be raised
Series 20 stock acquisition rights: ¥528 million. Series 16 stock acquisition rights: ¥1,463 million. Approximate net proceeds: Not disclosed
Specific use of funds
Development costs for a regenerative medicine product targeting chronic limb-threatening ischemiaAmount ¥400 million / Scheduled timing of expenditures December 2025 to December 2026
Technology and clinical research expenses related to introducing new technologies for specified processed cell products and strengthening the evidence baseAmount ¥655 million / Scheduled timing of expenditures January 2027 to December 2028
Promotional expenses related to the cell processing businessAmount ¥196 million / Scheduled timing of expenditures December 2025 to December 2027
Working capital for headquarters operationsAmount ¥598 million / Scheduled timing of expenditures December 2025 to December 2026
Expenses related to the development of regenerative medicine productsAmount ¥100 million / Scheduled timing of expenditures August 2025 to December 2026
Technology and clinical research expenses related to introducing new technologies for specified processed cell products and strengthening the evidence baseAmount ¥451 million / Scheduled timing of expenditures January 2027 to December 2028
Expenses related to the research and development of HSP105 in a joint research project with the National Cancer CenterAmount ¥335 million / Scheduled timing of expenditures July 2020 to September 2026
Working capital for headquarters operationsAmount ¥201 million / Scheduled timing of expenditures October 2026–December 2028
Expenses related to the research and development of BAR-T technology in a joint research project with Kyoto Prefectural University of MedicineAmount ¥53 million / Scheduled timing of expenditures July 2020 to December 2022
Joint research expenses toward the commercialization of a regenerative medicine product for the treatment of chronic heart failureAmount ¥170 million / Scheduled timing of expenditures December 2022 to March 2023
Working capital for headquarters operationsAmount ¥152 million / Scheduled timing of expenditures December 2022 to March 2023
Terms of the stock acquisition rights
Exercise price
Although the document states that the stock acquisition rights have an exercise price adjustment provision, the initial exercise price, details of the adjustment provision and floor price are Not disclosed
Number of Stock Acquisition Rights
Series 20: The total number issued and the number of rights remaining unexercised are Not disclosed. Exercise was completed for 190,501 rights (19,050,100 shares). Series 16: Exercise was completed for all 164,000 rights (16,400,000 shares), with 0 rights remaining unexercised
Most recent equity financing
Timing 3 December 2025 / Type 20th Series of Stock Acquisition Rights issued through a third-party allotment (with an exercise price adjustment clause) / Amount ¥528 million in funds raised, Timing Mentioned in a disclosure dated March 2026 / Type Sixteenth Series of Stock Acquisition Rights / Amount ¥1,463 million in funds raised
Impact on Business Performance
There is no impact on the financial results for the fiscal year ending September 2026 from this matter. The impact on performance for the fiscal year ending September 2027 and beyond is under consideration, including reflecting it in the earnings forecasts to be announced in the future.
| Item | Details |
|---|---|
| Type of issuance or disposal | Change in the Use of Proceeds for Series 20 Stock Acquisition Rights through a Third-Party Allotment (with an Exercise Price Adjustment Provision) and Series 16 Stock Acquisition Rights |
| Number of shares to be issued or disposed of | Exercise was completed for all 190,501 Series 20 stock acquisition rights (19,050,100 shares). Exercise was completed for all 164,000 Series 16 stock acquisition rights (16,400,000 shares). |
| Amount of funds to be raised | Series 20 stock acquisition rights: ¥528 million. Series 16 stock acquisition rights: ¥1,463 million. Approximate net proceeds: Not disclosed |
| Specific use of funds | Details Development costs for a regenerative medicine product targeting chronic limb-threatening ischemia / Amount ¥400 million / Scheduled timing of expenditures December 2025 to December 2026, Details Technology and clinical research expenses related to introducing new technologies for specified processed cell products and strengthening the evidence base / Amount ¥655 million / Scheduled timing of expenditures January 2027 to December 2028, Details Promotional expenses related to the cell processing business / Amount ¥196 million / Scheduled timing of expenditures December 2025 to December 2027, Details Working capital for headquarters operations / Amount ¥598 million / Scheduled timing of expenditures December 2025 to December 2026, Details Expenses related to the development of regenerative medicine products / Amount ¥100 million / Scheduled timing of expenditures August 2025 to December 2026, Details Technology and clinical research expenses related to introducing new technologies for specified processed cell products and strengthening the evidence base / Amount ¥451 million / Scheduled timing of expenditures January 2027 to December 2028, Details Expenses related to the research and development of HSP105 in a joint research project with the National Cancer Center / Amount ¥335 million / Scheduled timing of expenditures July 2020 to September 2026, Details Working capital for headquarters operations / Amount ¥201 million / Scheduled timing of expenditures October 2026–December 2028, Details Expenses related to the research and development of BAR-T technology in a joint research project with Kyoto Prefectural University of Medicine / Amount ¥53 million / Scheduled timing of expenditures July 2020 to December 2022, Details Joint research expenses toward the commercialization of a regenerative medicine product for the treatment of chronic heart failure / Amount ¥170 million / Scheduled timing of expenditures December 2022 to March 2023, Details Working capital for headquarters operations / Amount ¥152 million / Scheduled timing of expenditures December 2022 to March 2023 |
| Exercise price | Although the document states that the stock acquisition rights have an exercise price adjustment provision, the initial exercise price, details of the adjustment provision and floor price are Not disclosed |
| Number of Stock Acquisition Rights | Series 20: The total number issued and the number of rights remaining unexercised are Not disclosed. Exercise was completed for 190,501 rights (19,050,100 shares). Series 16: Exercise was completed for all 164,000 rights (16,400,000 shares), with 0 rights remaining unexercised |
| Most recent equity financing | Timing 3 December 2025 / Type 20th Series of Stock Acquisition Rights issued through a third-party allotment (with an exercise price adjustment clause) / Amount ¥528 million in funds raised, Timing Mentioned in a disclosure dated March 2026 / Type Sixteenth Series of Stock Acquisition Rights / Amount ¥1,463 million in funds raised |
| Impact on Business Performance | There is no impact on the financial results for the fiscal year ending September 2026 from this matter. The impact on performance for the fiscal year ending September 2027 and beyond is under consideration, including reflecting it in the earnings forecasts to be announced in the future. |
Items this document does not state (20)
Issue price and disposal priceTotal issue valueEstimated issuance expensesPayment dateIntended allotteeIntended allottee's holding policyDilution RateTotal number of issued sharesBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMajor shareholders after the offering
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The stated reasons are the discontinuation of development of the regenerative medicine product, the consolidation and review of research and development projects, a shift in focus toward the clinical application of specified processed cell products and clinical research, and the need to secure working capital for head office operations.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.